Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Ovarian Neoplasms 5Neoplasms 5Colorectal Neoplasms 5Prostatic Neoplasms 4Glioblastoma 4Solitary Fibrous Tumor, Pleural 3Mesothelioma, Malignant 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Lung Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Uveal Melanoma 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hypertension 1

Interventions

Sunitinib 19Everolimus 17Bevacizumab 13aldesleukin 11Sorafenib 11Interleukin-2 10Cyclophosphamide 10Axitinib 10Nivolumab 9fludarabine phosphate 7fludarabine 7pembrolizumab 5Gemcitabine 5temsirolimus 4pazopanib 4Ipilimumab 4peginterferon alfa-2b 3durvalumab 3cabozantinib 3Radiosurgery 3Interferon-alpha 3Granulocyte-Macrophage Colony-Stimulating Factor 3Filgrastim 3Erlotinib Hydrochloride 3Cryosurgery 3vandetanib 2spartalizumab 2perflutren 2ixabepilone 2chiron 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Kidney Neoplasms × cediranib × Clear all
NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma

AstraZeneca

Phase 2 Completed
105 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡